ADC Conjugation Kit (MMAE, 1mg, for human IgG4&mouse IgG2a)

Antibody-drug conjugates (ADCs) deliver potent cytotoxic drugs specifically to tumor cells, thereby enhancing antitumor efficacy and reducing the adverse systemic effects of the cytotoxic drugs. This kit is developed based on interchain cysteine conjugation technology: the interchain disulfide bonds of antibodies can be reduced to generate endogenous interchain cysteine residues, and payload drugs with maleimide functional groups can specifically conjugate to these cysteine residues to form structurally stable ADCs. Relying on this classic conjugation strategy, the kit enables a rapid and controllable ADC preparation process that takes only 3 hours in total, yielding a product with over 90% purity. The ADC Conjugation Kit provides a reliable experimental tool for ADC drug screening and mechanism research.

The ADC Conjugation Kit is designed to conjugate human IgG4 or mouse IgG2a and cytotoxic payloads MMAE through thiol and maleimide reaction chemistry. The ADC products can be used in cellular or animal experiments for the screening of suitable ADC candidates.

It is for research use only.

• Short Conjugation Time: Generates antibody-drug conjugates (ADCs) within 3 hours.
• High Purity & Activity Preserved: ADC monomer content > 90% with high bioactivity retained.
• No Need for High-Concentration Antibodies: Reaction feasible with only 2 mg/mL of antibodies.
• Simple Purification: Purification completed in 15 minutes using spin desalting columns.

BoxA: This product remains stable when stored at -20℃ for 24 months.

BoxB: This product remains stable when stored at 2-8℃ for 24 months.

Please ensure use prior to the expiration date indicated on the packaging.